FDA Approvals & Rejections - GSK's Lynavoy received FDA approval as the first treatment for cholestatic pruritus in adults with primary biliary cholangitis, supported by Phase 3 GLISTEN trial data showing significant reductions in itching and sleep disturbance compared to placebo [2] - Knight Therapeutics gained approval in Brazil for MINJUVI in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, backed by clinical data demonstrating meaningful response rates [4][5] - Novartis' Cosentyx was approved for treating moderate to severe hidradenitis suppurativa in adolescents aged 12 and older, making it the first IL-17A inhibitor approved for this age group [6][7] - Myriad Genetics' MyChoice CDx test was approved as a companion diagnostic for GSK's Zejula in advanced ovarian cancer, being the only FDA-approved HRD test for this purpose [9][10] - Aldeyra Therapeutics faced another FDA rejection for Reproxalap in dry eye disease, with shares plummeting nearly 75% following the Complete Response Letter citing lack of substantial evidence [11][12][13] - Telix Pharmaceuticals resubmitted its NDA for TLX101-Px, an investigational PET imaging agent for glioma, addressing previous FDA concerns [14][15] - Rhythm Pharmaceuticals received FDA approval for IMCIVREE to treat acquired hypothalamic obesity, supported by Phase 3 TRANSCEND trial results showing a significant BMI reduction [16] - Novo Nordisk's Wegovy HD was approved for weight loss, showing an average weight loss of 20.7% in the STEP UP trial, with a launch expected in April 2026 [17][18] Clinical Trials - Breakthroughs & Setbacks - Ascendis Pharma reported positive results from its Phase 2 trial for TransCon hGH in Turner syndrome, showing similar annualized height velocity compared to daily somatropin [24][25] - CytomX Therapeutics announced positive expansion data for Varseta-M in late-line metastatic colorectal cancer, with a disease control rate of 88% across evaluated doses [26][28][29] - Rhythm Pharmaceuticals' EMANATE trial missed its primary endpoint but showed significant BMI reductions in specific genetic subgroups, with no new safety concerns reported [30][32] - Sana Biotechnology reported positive 14-month results from a study on UP421 for type 1 diabetes, demonstrating sustained function of pancreatic beta cells and successful immune evasion [33][34][35] - Immutep discontinued its Phase III trial of Eftilagimod Alfa in first-line non-small cell lung cancer due to futility as recommended by the Independent Data Monitoring Committee [36][37]

2026年3月16日，Rhythm Pharmaceuticals公布了其减肥药Setmelanotide在全球三期临床试验EMANATE中的主要结果。令人遗憾的是，该试验 未能达到预设的主要终点，这意味着药物在多个罕见遗传性肥胖亚组中的效果未能如预期显现。 Setmelanotide的机制与临床背景 Setmelanotide是一款首创的MC4R（黑素皮质素4受体）激动剂，主要通过修复下丘脑的MC4R通路，调控食欲与能量平衡，直接作用于由遗传 性基因缺陷引发的肥胖。这一机制使其成为针对特定基因缺陷导致的遗传性肥胖（如Bardet-Biedl综合征及POMC、PCSK1、LEPR等基因缺 陷）的一项潜力药物。 整理 | GLP1减重宝典内容团队 Setmelanotide（商品名：IMCIVREE®）已经获得了美国FDA的批准，并被用于治疗2岁及以上儿童和成人的遗传性肥胖症。然而，随着全球三 期临床试验的展开，药物的实际疗效却未能达到预期。 LEPR 杂合突变组（N=23）：安慰剂校正后BMI下降3.6%（p=0.94），未见有效疗效。 SRC1（NCOA1）组（N=73）：安慰剂校正后BMI下降4.0%（p ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Rhythm Pharmaceuticals announced positive preliminary data from an exploratory Phase II trial of setmelanotide for Prader-Willi syndrome, indicating a potential efficacy signal [2]. Group 1: Company Overview - Rhythm Pharmaceuticals is conducting research on setmelanotide, which is being evaluated for its effectiveness in treating Prader-Willi syndrome [2][3]. - The company held a conference call to discuss the trial results, with key presentations from its leadership and external experts [1][3]. Group 2: Trial Details - The Phase II trial is exploratory in nature and aims to assess the efficacy of setmelanotide in patients with Prader-Willi syndrome [2][3]. - Dr. Jennifer Miller from the University of Florida is the principal investigator for this Phase II trial, highlighting the collaboration with academic institutions [3].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Clinical Trial Results - Bivamelagon achieved statistically significant BMI reductions in patients with acquired hypothalamic obesity at 14 weeks[5] - At 14 weeks, the 200mg Bivamelagon group saw a mean BMI reduction of 268%, the 400mg group saw a mean BMI reduction of 769%, and the 600mg group saw a mean BMI reduction of 931%[27] - In the placebo group, there was a mean BMI increase of 218% from baseline at 14 weeks[27] - A significant percentage of patients achieved clinically meaningful BMI reductions: 167% in the 200mg Bivamelagon group, 714% in the 400mg group, and 75% in the 600mg group achieved at least a 5% BMI reduction[33] - Bivamelagon also achieved meaningful reductions in 'most' hunger scores at Week 14[44] Safety and Tolerability - Safety and tolerability results were generally consistent with an MC4R MOA and setmelanotide trials in acquired hypothalamic obesity, with limited instances of localized hyperpigmentation[5] - The most common AEs with >=10% in all BIVA dosing (N=21) were nausea, diarrhea, vomiting, and headache[47] Market Opportunity and Future Development - Rhythm Pharmaceuticals intends to request an End-of-Phase 2 meeting with the FDA with intentions to move forward to Phase 3[5] - The company estimates the U S prevalence of acquired hypothalamic obesity to be 5,000 – 10,000 patients[13] - U S patent protection for bivamelagon and RM-718 extends into the 2040s[13]

Core Insights - Rhythm Pharmaceuticals announced positive topline results from its Phase 2 trial of bivamelagon, showing significant BMI reductions in patients with acquired hypothalamic obesity [2][3] - The company plans to engage with regulatory authorities for a Phase 3 trial design and has requested an End-of-Phase 2 meeting with the U.S. FDA [7] Group 1: Trial Results - Bivamelagon achieved BMI reductions of -9.3% in the 600mg cohort and -7.7% in the 400mg cohort at 14 weeks [1][4] - A post-hoc analysis indicated that the BMI reductions from bivamelagon were consistent with those achieved by setmelanotide in similar patient populations [3][5] - Patients reported a mean reduction of -2.8 points in hunger scores in both the 600mg and 400mg cohorts [1][3] Group 2: Safety and Tolerability - The trial demonstrated safety and tolerability consistent with MC4R agonism, with limited instances of localized hyperpigmentation observed [4][6] - The most common adverse events included mild diarrhea and nausea, with one serious adverse event reported [6] Group 3: Next Steps and Regulatory Plans - Rhythm plans to seek input from U.S. and EU regulatory authorities regarding the Phase 3 trial design for bivamelagon [7] - The company is refining the formulation of bivamelagon to potentially improve tolerability before initiating the Phase 3 trial [7] Group 4: Company Background - Rhythm Pharmaceuticals is focused on transforming the lives of patients with rare neuroendocrine diseases and has in-licensed bivamelagon from LG Chem, Ltd [2][13] - The company’s lead asset, setmelanotide, is already approved for treating certain types of obesity [13][14]